Back to Browse Journals » Breast Cancer: Targets and Therapy » Volume 3

Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women

Authors Vogel VG

Published 20 October 2011 Volume 2011:3 Pages 127—137


Review by Single-blind

Peer reviewer comments 5

Victor G Vogel
Cancer Institute, Geisinger Health System, Danville, PA, USA

Abstract: Risk factors allow us to define women who are at increased lifetime risk for breast cancer, and the most important factor is age. Benign breast disease increases risk, and the most important histologies are atypical lobular or ductal hyperplasia and lobular carcinoma in situ. Family history of breast cancer among first-degree relatives (mother, sisters, daughters) also increases risk. Quantitative measures of risk give accurate predictions of breast cancer incidence for groups of women but not for individual subjects. Multiple published, randomized controlled trials, which employed selective estrogen receptor (ER) modulators (SERMs), have demonstrated consistent reductions of 35% or greater in the risk of ER-positive invasive and noninvasive breast cancer in postmenopausal women. Professional organizations in the US now recommend the use of SERMs to reduce the risk of breast cancer in high-risk, postmenopausal women. Raloxifene and tamoxifen reduce the risk of ER-positive invasive breast cancer with equal efficacy, but raloxifene is associated with a lower risk of thromboembolic disease, benign uterine conditions, and cataracts than tamoxifen in postmenopausal women. No evidence exists establishing whether a reduction in breast cancer risk from either agent translates into reduced breast cancer mortality. Overall quality of life is similar with raloxifene or tamoxifen, but the incidence of dyspareunia, weight gain, and musculoskeletal complaints is higher with raloxifene use, whereas vasomotor symptoms, bladder incontinence, gynecologic symptoms, and leg cramps were higher with tamoxifen use.

Keywords: selective estrogen receptor modulators (SERMs), raloxifene, risk reduction, chemoprevention

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] View Full Text [HTML] 


Other article by this author:

Readers of this article also read:

Developments in flexible endoscopic surgery: a review

Feussner H, Becker V, Bauer M, Kranzfelder M, Schirren R, Lüth T, Meining A, Wilhelm D

Clinical and Experimental Gastroenterology 2015, 8:31-42

Published Date: 18 December 2014

Crenolanib, a PDGFR inhibitor, suppresses lung cancer cell proliferation and inhibits tumor growth in vivo

Wang P, Song L, Ge H, Jin P, Jiang Y, Hu W, Geng N

OncoTargets and Therapy 2014, 7:1761-1768

Published Date: 26 September 2014

Positron emission tomographic monitoring of dual phosphatidylinositol-3-kinase and mTOR inhibition in anaplastic large cell lymphoma

Graf N, Li ZL, Herrmann K, Weh D, Aichler M, Slawska J, Walch A, Peschel C, Schwaiger M, Buck AK, Dechow T, Keller U

OncoTargets and Therapy 2014, 7:789-798

Published Date: 23 May 2014

Lung penetration and patient adherence considerations in the management of asthma: role of extra-fine formulations [Corrigendum]

Scichilone N, Spatafora M, Battaglia S, Arrigo R, Benfante A, Bellia V

Journal of Asthma and Allergy 2013, 6:67-68

Published Date: 24 May 2013

New developments in the treatment of HER2-positive breast cancer

Nahta R

Breast Cancer: Targets and Therapy 2012, 4:53-64

Published Date: 7 May 2012

Treating glioblastoma multiforme with selective high-dose liposomal doxorubicin chemotherapy induced by repeated focused ultrasound

Yang FY, Teng MC, Lu M, Liang HF, Lee YR, Yen CC, Liang ML, Wong TT

International Journal of Nanomedicine 2012, 7:965-974

Published Date: 21 February 2012

Synthesis, characterization, and in vitro evaluation of novel polymer-coated magnetic nanoparticles for controlled delivery of doxorubicin

Akbarzadeh A, Zarghami N, Mikaeili H, Asgari D, Goganian AM, Khiabani HK, Samiei M, Davaran S

Nanotechnology, Science and Applications 2012, 5:13-25

Published Date: 7 February 2012

Gelatinase-stimuli strategy enhances the tumor delivery and therapeutic efficacy of docetaxel-loaded poly(ethylene glycol)-poly(ε-caprolactone) nanoparticles

Liu Q, Li RT, Qian HQ, Yang M, Zhu ZS, Wu W, Qian XP, Yu LX, Jiang XQ, Liu BR

International Journal of Nanomedicine 2012, 7:281-295

Published Date: 20 January 2012

Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension

Bruce I Gaynes, Anne Onyekwuluje

Clinical Ophthalmology 2008, 2:355-368

Published Date: 6 June 2008